Deciphering immune microenvironment and cell evasion mechanisms in human gliomas

Gliomas are considered one of the most malignant cancers in the body. Despite current therapies, including surgery, chemotherapy, and radiotherapy, these tumors usually recur with more aggressive and resistant phenotypes. Indeed, the survival following these conventional therapies is very poor, whic...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 13; p. 1135430
Main Authors Rafii, Soumaya, Kandoussi, Sarah, Ghouzlani, Amina, Naji, Oumayma, Reddy, Konala Priyanka, Ullah Sadiqi, Rizwan, Badou, Abdallah
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 19.05.2023
Subjects
glioma
glioma cell evasion
immune checkpoints
immune microenvironment
immunotherapy
Oncology
therapy resistance
glioma
immune microenvironment
glioma cell evasion
immunotherapy
immune checkpoints
therapy resistance
Online AccessGet full text

Cover

Abstract Gliomas are considered one of the most malignant cancers in the body. Despite current therapies, including surgery, chemotherapy, and radiotherapy, these tumors usually recur with more aggressive and resistant phenotypes. Indeed, the survival following these conventional therapies is very poor, which makes immunotherapy the subject of active research at present. The anti-tumor immune response could also be considered a prognostic factor since each stage of cancer development is regulated by immune cells. However, glioma microenvironment contains malignant cells that secrete numerous chemokines, cytokines and growth factors, promoting the infiltration of immunosuppressive cells into the tumor, which limit the functioning of the immune system against glioma cells. Recently, researchers have been able to reverse the immune resistance of cancer cells and thus activate the anti-tumor immune response through different immunotherapy strategies. Here, we review the general concept of glioma’s immune microenvironment and report the impact of its distinct components on the anti-tumor immune response. We also discuss the mechanisms of glioma cell evasion from the immune response and pinpoint some potential therapeutic pathways, which could alleviate such resistance.
AbstractList Gliomas are considered one of the most malignant cancers in the body. Despite current therapies, including surgery, chemotherapy, and radiotherapy, these tumors usually recur with more aggressive and resistant phenotypes. Indeed, the survival following these conventional therapies is very poor, which makes immunotherapy the subject of active research at present. The anti-tumor immune response could also be considered a prognostic factor since each stage of cancer development is regulated by immune cells. However, glioma microenvironment contains malignant cells that secrete numerous chemokines, cytokines and growth factors, promoting the infiltration of immunosuppressive cells into the tumor, which limit the functioning of the immune system against glioma cells. Recently, researchers have been able to reverse the immune resistance of cancer cells and thus activate the anti-tumor immune response through different immunotherapy strategies. Here, we review the general concept of glioma’s immune microenvironment and report the impact of its distinct components on the anti-tumor immune response. We also discuss the mechanisms of glioma cell evasion from the immune response and pinpoint some potential therapeutic pathways, which could alleviate such resistance.
Gliomas are considered one of the most malignant cancers in the body. Despite current therapies, including surgery, chemotherapy, and radiotherapy, these tumors usually recur with more aggressive and resistant phenotypes. Indeed, the survival following these conventional therapies is very poor, which makes immunotherapy the subject of active research at present. The anti-tumor immune response could also be considered a prognostic factor since each stage of cancer development is regulated by immune cells. However, glioma microenvironment contains malignant cells that secrete numerous chemokines, cytokines and growth factors, promoting the infiltration of immunosuppressive cells into the tumor, which limit the functioning of the immune system against glioma cells. Recently, researchers have been able to reverse the immune resistance of cancer cells and thus activate the anti-tumor immune response through different immunotherapy strategies. Here, we review the general concept of glioma's immune microenvironment and report the impact of its distinct components on the anti-tumor immune response. We also discuss the mechanisms of glioma cell evasion from the immune response and pinpoint some potential therapeutic pathways, which could alleviate such resistance.Gliomas are considered one of the most malignant cancers in the body. Despite current therapies, including surgery, chemotherapy, and radiotherapy, these tumors usually recur with more aggressive and resistant phenotypes. Indeed, the survival following these conventional therapies is very poor, which makes immunotherapy the subject of active research at present. The anti-tumor immune response could also be considered a prognostic factor since each stage of cancer development is regulated by immune cells. However, glioma microenvironment contains malignant cells that secrete numerous chemokines, cytokines and growth factors, promoting the infiltration of immunosuppressive cells into the tumor, which limit the functioning of the immune system against glioma cells. Recently, researchers have been able to reverse the immune resistance of cancer cells and thus activate the anti-tumor immune response through different immunotherapy strategies. Here, we review the general concept of glioma's immune microenvironment and report the impact of its distinct components on the anti-tumor immune response. We also discuss the mechanisms of glioma cell evasion from the immune response and pinpoint some potential therapeutic pathways, which could alleviate such resistance.
Author Badou, Abdallah
Reddy, Konala Priyanka
Rafii, Soumaya
Kandoussi, Sarah
Ghouzlani, Amina
Naji, Oumayma
Ullah Sadiqi, Rizwan
AuthorAffiliation 3 Faculty of Science and Technology, Middlesex University , London , United Kingdom
4 Mohammed VI Center for Research and Innovation, Rabat, Morocco and Mohammed VI University of Sciences and Health , Casablanca , Morocco
1 Immuno-Genetics and Human Pathologies Laboratory, Faculty of Medicine and Pharmacy, Hassan II University , Casablanca , Morocco
2 Faculty of Medicine, Medical University of Pleven , Pleven , Bulgaria
AuthorAffiliation_xml – name: 4 Mohammed VI Center for Research and Innovation, Rabat, Morocco and Mohammed VI University of Sciences and Health , Casablanca , Morocco
– name: 1 Immuno-Genetics and Human Pathologies Laboratory, Faculty of Medicine and Pharmacy, Hassan II University , Casablanca , Morocco
– name: 3 Faculty of Science and Technology, Middlesex University , London , United Kingdom
– name: 2 Faculty of Medicine, Medical University of Pleven , Pleven , Bulgaria
Author_xml – sequence: 1
  givenname: Soumaya
  surname: Rafii
  fullname: Rafii, Soumaya
– sequence: 2
  givenname: Sarah
  surname: Kandoussi
  fullname: Kandoussi, Sarah
– sequence: 3
  givenname: Amina
  surname: Ghouzlani
  fullname: Ghouzlani, Amina
– sequence: 4
  givenname: Oumayma
  surname: Naji
  fullname: Naji, Oumayma
– sequence: 5
  givenname: Konala Priyanka
  surname: Reddy
  fullname: Reddy, Konala Priyanka
– sequence: 6
  givenname: Rizwan
  surname: Ullah Sadiqi
  fullname: Ullah Sadiqi, Rizwan
– sequence: 7
  givenname: Abdallah
  surname: Badou
  fullname: Badou, Abdallah
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37274252$$D View this record in MEDLINE/PubMed
BookMark eNp1kk1v1DAQhi1UREvpD-CCcuSyi7_iOCeEylelSnAAiZs1sSe7rmJ7sZOV-Pd42S1qkfDF1njmee2Z9zk5iykiIS8ZXQuh-zdjinbNKRdrxkQrBX1CLjgXctVL8ePswfmcXJVyR-tSLWVUPCPnouOd5C2_IF_fo_W7LWYfN40PYYnYBG9zwrj3OcWAcW4gusbiNDW4h-JTbALaLURfQml8bLZLgNhsJp8ClBfk6QhTwavTfkm-f_zw7frz6vbLp5vrd7crK5WaVwNX9cnaWdGOSole4ag5gpC9hq5VApXqeqftwKiWTCNDDqAFg9G5Ee0gLsnNkesS3Jld9gHyL5PAmz-BlDcG8uzthEYqR62lcnCsk5ZWMWG7HsEJUGywUFlvj6zdMgR0tv45w_QI-vgm-q3ZpL1htf1t2-tKeH0i5PRzwTKb4MuhZRAxLcVwzXlH21bxmvrqodhflfuZ1ITumFCnUErG0Vg_w1z7XrX9VEXNwQDmYABzMIA5GaBWsn8q7-H_r_kN48a1fw
CitedBy_id crossref_primary_10_3389_fimmu_2024_1399754
crossref_primary_10_1186_s12967_024_05309_1
crossref_primary_10_3390_biology13100846
crossref_primary_10_3389_fonc_2023_1254694
crossref_primary_10_1089_jir_2023_0050
crossref_primary_10_3389_fonc_2025_1507632
Cites_doi 10.1016/j.trecan.2019.05.006
10.1158/1078-0432.CCR-15-1535
10.1007/s10147-016-0959-z
10.1093/neuonc/nop023
10.1016/j.jconrel.2020.01.005
10.18632/oncotarget.25061
10.1002/ijc.30912
10.1016/j.stem.2014.01.005
10.1016/j.celrep.2016.10.052
10.1158/0008-5472.CAN-16-2310
10.1158/1535-7163.MCT-09-0734
10.1007/s12035-017-0569-4
10.1016/j.biocel.2014.10.005
10.1158/1078-0432.CCR-12-3314
10.1007/s00415-017-8695-5
10.1038/bjc.2014.162
10.1038/cr.2016.151
10.1080/2162402X.2017.1412909
10.2174/1570164611310030007
10.1186/s13045-021-01102-5
10.3390/cancers11020186
10.1038/nrc.2015.5
10.1016/j.cell.2016.12.022
10.1038/labinvest.2017.19
10.21873/anticanres.12824
10.1038/nrc1782
10.1038/s41590-018-0135-x
10.26502/acbr.50170134
10.1126/scitranslmed.aaa0984
10.3390/cells8020104
10.1002/JLB.MR0318-097R
10.4049/jimmunol.172.1.104
10.2147/OTT.S52365
10.1093/neuonc/noz185
10.1200/JCO.2014.58.3377
10.2217/fon.14.238
10.1038/nri1733
10.1038/s43018-021-00228-2
10.3389/fsurg.2016.00011
10.1038/nature14189
10.1172/jci.insight.99048
10.1093/neuonc/now061
10.1038/s41590-019-0433-y
10.1186/1471-2172-10-11
10.1038/d41586-018-05883-7
10.1097/NEN.0000000000000183
10.1126/scitranslmed.aae0105
10.1016/j.canlet.2021.05.038
10.3892/ol.2016.4142
10.1126/science.aaf0683
10.1016/j.brainres.2014.07.050
10.1038/s41388-018-0261-9
10.3389/fonc.2018.00464
10.1093/neuonc/not159
10.3389/fimmu.2014.00174
10.3389/fimmu.2020.01191
10.1158/2326-6066.CIR-19-0240
10.3892/mmr.2014.2151
10.1038/s41591-019-0349-y
10.1158/2326-6066.CIR-13-0013
10.1016/j.ccell.2015.03.001
10.1038/s41598-019-51063-6
10.3389/fimmu.2021.637146
10.18632/oncotarget.12702
10.1080/21645515.2017.1388481
10.1038/s41577-021-00652-6
10.3390/cancers11040537
10.1371/journal.pone.0016195
10.3390/cancers11030312
10.18632/oncotarget.25131
10.7314/apjcp.2013.14.1.309
10.3389/fimmu.2021.679425
10.3390/ijms24076688
10.1186/s12935-019-0972-1
10.3389/fonc.2020.608609
10.1182/blood-2014-03-563940
10.1007/978-3-030-54879-7_2
10.1038/s41467-019-11719-3
10.1002/ijc.27712
10.1093/neuonc/nor042
10.1007/978-3-030-02505-2_1
10.1038/sj.bjc.6601268
10.1007/s11060-019-03172-5
10.1186/s12974-019-1535-z
10.1016/j.wneu.2017.04.041
10.1016/j.biopha.2019.109610
10.1084/jem.20200913
10.1038/s41591-018-0337-7
10.1038/nn.3161
10.7150/thno.33114
10.1007/s00401-016-1545-1
10.1007/s10072-017-3002-x
10.1016/j.ymthe.2018.02.001
10.1016/j.cell.2016.03.001
10.1002/ijc.32531
10.1038/ncb3090
10.1038/nature14432
10.1016/S1470-2045(11)70196-6
10.1038/s41388-019-0737-2
10.1038/nri2144
10.1093/neuonc/nov034
10.1080/08998280.2016.11929449
10.1517/14712598.2014.927432
10.1371/journal.pone.0169932
10.1007/s00262-012-1319-0
10.1101/309807
10.1172/jci.insight.123837
10.3390/ijms19102879
10.1016/j.mrfmmm.2004.06.054
10.1111/j.1600-065X.2006.00445.x
10.2147/CMAR.S210545
10.1016/j.yexcr.2012.11.018
10.1038/cddis.2016.318
10.2147/OTT.S299977
ContentType Journal Article
Copyright Copyright © 2023 Rafii, Kandoussi, Ghouzlani, Naji, Reddy, Ullah Sadiqi and Badou.
Copyright © 2023 Rafii, Kandoussi, Ghouzlani, Naji, Reddy, Ullah Sadiqi and Badou 2023 Rafii, Kandoussi, Ghouzlani, Naji, Reddy, Ullah Sadiqi and Badou
Copyright_xml – notice: Copyright © 2023 Rafii, Kandoussi, Ghouzlani, Naji, Reddy, Ullah Sadiqi and Badou.
– notice: Copyright © 2023 Rafii, Kandoussi, Ghouzlani, Naji, Reddy, Ullah Sadiqi and Badou 2023 Rafii, Kandoussi, Ghouzlani, Naji, Reddy, Ullah Sadiqi and Badou
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fonc.2023.1135430
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
CrossRef
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
ExternalDocumentID oai_doaj_org_article_46d0cc04bd174c03963c79ead3a61bca
PMC10235598
37274252
10_3389_fonc_2023_1135430
Genre Journal Article
Review
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c466t-b264308dc35f66396ef82ea3498a7563e6679d8cb108418e1e2aa831afddfecb3
IEDL.DBID M48
ISSN 2234-943X
IngestDate Wed Aug 27 01:24:42 EDT 2025
Thu Aug 21 18:37:14 EDT 2025
Fri Jul 11 04:45:54 EDT 2025
Thu Apr 03 07:07:55 EDT 2025
Tue Jul 01 02:58:13 EDT 2025
Thu Apr 24 22:56:54 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords glioma
immune microenvironment
glioma cell evasion
immunotherapy
immune checkpoints
therapy resistance
Language English
License Copyright © 2023 Rafii, Kandoussi, Ghouzlani, Naji, Reddy, Ullah Sadiqi and Badou.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c466t-b264308dc35f66396ef82ea3498a7563e6679d8cb108418e1e2aa831afddfecb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Rongrong Zhou, Central South University, China; Cristiana Tanase, Victor Babes National Institute of Pathology (INCDVB), Romania
Edited by: Wen Cheng, The First Affiliated Hospital of China Medical University, China
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fonc.2023.1135430
PMID 37274252
PQID 2822705562
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_46d0cc04bd174c03963c79ead3a61bca
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10235598
proquest_miscellaneous_2822705562
pubmed_primary_37274252
crossref_citationtrail_10_3389_fonc_2023_1135430
crossref_primary_10_3389_fonc_2023_1135430
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-05-19
PublicationDateYYYYMMDD 2023-05-19
PublicationDate_xml – month: 05
  year: 2023
  text: 2023-05-19
  day: 19
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in oncology
PublicationTitleAlternate Front Oncol
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Rodrigues (B30) 2010; 12
Gabrusiewicz (B98) 2018; 7
Colella (B116) 2019; 11
Zou (B117) 2014; 10
Wang (B101) 2019; 16
Yang (B44) 2017; 141
Stephen (B70) 2018
Han (B38) 2014; 57
Beiko (B77) 2014; 16
Rafii (B61) 2023; 24
Miyauchi (B3) 2018; 265
Cruceru (B33) 2013; 6
Guo (B111) 2020; 320
Chen (B19) 2017; 77
Tanase (B96) 2013; 10
Kahlon (B106) 2016; 29
Domenis (B113) 2017; 12
Kong (B81) 2018; 14
Gordon (B18) 2005; 5
Tanaka (B53) 2017; 27
Alban (B58) 2018; 3
Wu (B69) 2019; 143
Platten (B110) 2018; 561
Kamphorst (B66) 2017; 355
Zhao (B68) 2019; 25
Raychaudhuri (B29) 2011; 13
Ghouzlani (B57) 2020; 4
Filiano (B11) 2015; 1617
Zhang (B25) 2016; 18
Alban (B34) 2020; 11
Ghiringhelli (B23) 2006; 214
Galstyan (B108) 2019; 10
Alessandrini (B90) 2019; 38
Pietras (B102) 2014; 14
Pituch (B87) 2018; 26
Ousman (B42) 2012; 15
Spitzer (B46) 2017; 168
Wang (B112) 2019; 9
D’Amico (B4) 2017; 103
Jackson (B5) 2019; 20
Abels (B95) 2019; 5
Louis (B7) 2016; 131
Chai (B31) 2019; 11
Martikainen (B89) 2019; 11
Wei (B99) 2010; 9
Razavi (B63) 2016; 3
Chiblak (B104) 2019; 4
Selby (B72) 2013; 1
Kim (B75) 2017; 23
Topalian (B60) 2015; 27
Da Ros (B105) 2018; 19
Cloughesy (B85) 2019; 25
Senft (B76) 2011; 12
Bloch (B51) 2013; 19
Wang (B17) 2021; 14
Ma (B21) 2021; 517
Bowman (B16) 2016; 17
Ding (B64) 2021; 14
Murakami (B26) 2018; 38
Louveau (B10) 2015; 523
Lee-Chang (B41) 2020; 218
Shibao (B82) 2018; 9
Hamanishi (B62) 2016; 21
Garg (B79) 2016; 8
Platten (B52) 2015; 17
Eagle (B22) 2007; 7
Zhang (B71) 2017; 8
Romani (B73) 2018; 8
Papandreou (B103) 2005; 569
Morvan (B24) 2016; 16
Andtbacka (B91) 2015; 33
Artis (B13) 2015; 517
Schiffer (B9) 2017; 38
Finney (B86) 2004; 172
Gieryng (B12) 2017; 97
Haabeth (B47) 2014; 5
Garzon-Muvdi (B28) 2018; 9
Phuphanich (B78) 2013; 62
Srivastava (B27) 2019; 11
de Visser (B8) 2006; 6
O’Rourke (B88) 2017; 9
Han (B43) 2014; 110
Ko (B93) 2018; 55
Ghouzlani (B2) 2021; 12
Liu (B74) 2016; 11
Ghouzlani (B65) 2021; 10
de Groot (B84) 2020; 22
Weenink (B50) 2019; 9
Whiteside (B54) 2014; 14
Jawhari (B115) 2016; 7
Wang (B48) 2018; 3
Lu (B59) 2019; 19
Raphael (B67) 2021; 12
Wei (B92) 2011; 6
Lee-Chang (B39) 2019; 7
Chirasani (B107) 2013; 132
Agnihotri (B83) 2021; 2
Sheng (B100) 2020; 121
Kennedy (B49) 2009; 10
Chraa (B35) 2019; 105
Zhang (B55) 2015; 8
Reynoso-Noverón (B1) 2021
B14
Tanase (B97) 2015; 11
Yamanaka (B80) 2003; 89
Zhou (B20) 2015; 17
Lee-Chang (B40) 2014; 124
Gielen (B15) 2015; 74
Zitvogel (B45) 2016; 165
Liu (B114) 2013; 14
(B6) 2018
Jain (B36) 2022; 22
Rui (B37) 2018; 19
Guo (B32) 2018; 37
Held-Feindt (B56) 2013; 319
Domblides (B94) 2019; 8
Kim (B109) 2019; 145
References_xml – volume: 5
  year: 2019
  ident: B95
  article-title: Glioma EVs contribute to immune privilege in the brain
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2019.05.006
– volume: 23
  year: 2017
  ident: B75
  article-title: Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-1535
– volume: 21
  year: 2016
  ident: B62
  article-title: PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
  publication-title: Int J Clin Oncol
  doi: 10.1007/s10147-016-0959-z
– volume: 12
  year: 2010
  ident: B30
  article-title: Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/nop023
– volume: 320
  start-page: 63
  year: 2020
  ident: B111
  article-title: Deliver anti-PD-L1 into brain by p-hydroxybenzoic acid to enhance immunotherapeutic effect for glioblastoma
  publication-title: J Controlled Release
  doi: 10.1016/j.jconrel.2020.01.005
– volume: 9
  year: 2018
  ident: B28
  article-title: Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.25061
– volume: 141
  year: 2017
  ident: B44
  article-title: MiR-15a/16 deficiency enhances anti-tumor immunity of glioma-infiltrating CD8+ T cells through targeting MTOR
  publication-title: Int J Cancer
  doi: 10.1002/ijc.30912
– volume: 14
  year: 2014
  ident: B102
  article-title: Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2014.01.005
– volume: 17
  year: 2016
  ident: B16
  article-title: Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2016.10.052
– volume: 77
  year: 2017
  ident: B19
  article-title: Cellular and molecular identity of tumor-associated macrophages in glioblastoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-16-2310
– volume: 9
  start-page: 67
  year: 2010
  ident: B99
  article-title: Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-09-0734
– volume: 55
  year: 2018
  ident: B93
  article-title: MDM2 degrades deacetylated nucleolin through ubiquitination to promote glioma stem-like cell enrichment for chemotherapeutic resistance
  publication-title: Mol Neurobiol
  doi: 10.1007/s12035-017-0569-4
– volume: 57
  year: 2014
  ident: B38
  article-title: Glioma cell-derived placental growth factor induces regulatory b cells
  publication-title: Int J Biochem Cell Biol
  doi: 10.1016/j.biocel.2014.10.005
– volume: 19
  year: 2013
  ident: B51
  article-title: Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-3314
– volume: 265
  year: 2018
  ident: B3
  article-title: Advances in immunotherapeutic research for glioma therapy
  publication-title: J Neurol
  doi: 10.1007/s00415-017-8695-5
– volume: 110
  year: 2014
  ident: B43
  article-title: Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2014.162
– volume: 27
  year: 2017
  ident: B53
  article-title: Regulatory T cells in cancer immunotherapy
  publication-title: Cell Res
  doi: 10.1038/cr.2016.151
– volume: 7
  start-page: e1412909
  year: 2018
  ident: B98
  article-title: Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2017.1412909
– volume: 10
  year: 2013
  ident: B96
  article-title: Anti-cancer therapies in high grade gliomas
  publication-title: Curr Proteomics
  doi: 10.2174/1570164611310030007
– volume: 14
  start-page: 92
  year: 2021
  ident: B64
  article-title: The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-021-01102-5
– volume: 11
  year: 2019
  ident: B89
  article-title: Virus-based immunotherapy of glioblastoma
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers11020186
– volume: 16
  start-page: 7
  year: 2016
  ident: B24
  article-title: NK cells and cancer: you can teach innate cells new tricks
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2015.5
– volume: 168
  start-page: 487
  year: 2017
  ident: B46
  article-title: Systemic immunity is required for effective cancer immunotherapy
  publication-title: Cell
  doi: 10.1016/j.cell.2016.12.022
– volume: 97
  start-page: 498
  year: 2017
  ident: B12
  article-title: Immune microenvironment of gliomas
  publication-title: Lab Invest
  doi: 10.1038/labinvest.2017.19
– volume: 38
  year: 2018
  ident: B26
  article-title: Novel human NK cell line carrying CAR targeting EGFRvIII induces antitumor effects in glioblastoma cells
  publication-title: Anticancer Res
  doi: 10.21873/anticanres.12824
– volume: 6
  start-page: 24
  year: 2006
  ident: B8
  article-title: Paradoxical roles of the immune system during cancer development
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1782
– volume: 19
  year: 2018
  ident: B37
  article-title: Reassessing b cell contributions in multiple sclerosis
  publication-title: Nat Immunol
  doi: 10.1038/s41590-018-0135-x
– volume: 4
  start-page: 691
  year: 2020
  ident: B57
  article-title: High expression levels of Foxp3 and VISTA in advanced human gliomas and impact on patient’s prognosis
  publication-title: Arch Clin Biomed Res
  doi: 10.26502/acbr.50170134
– volume: 9
  year: 2017
  ident: B88
  article-title: Single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aaa0984
– volume: 8
  year: 2019
  ident: B94
  article-title: Control of the antitumor immune response by cancer metabolism
  publication-title: Cells
  doi: 10.3390/cells8020104
– volume: 105
  year: 2019
  ident: B35
  article-title: Lymphocyte subsets in cancer immunity: friends or foes
  publication-title: J Leukoc Biol
  doi: 10.1002/JLB.MR0318-097R
– volume: 172
  year: 2004
  ident: B86
  article-title: Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain
  publication-title: J Immunol
  doi: 10.4049/jimmunol.172.1.104
– volume: 6
  year: 2013
  ident: B33
  article-title: Signal transduction molecule patterns indicating potential glioblastoma therapy approaches
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S52365
– volume: 22
  year: 2020
  ident: B84
  article-title: Window-of-Opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/noz185
– volume: 33
  year: 2015
  ident: B91
  article-title: Talimogene laherparepvec improves durable response rate in patients with advanced melanoma
  publication-title: JCO
  doi: 10.1200/JCO.2014.58.3377
– volume: 11
  year: 2015
  ident: B97
  article-title: Circulating biomarker panels for targeted therapy in brain tumors
  publication-title: Future Oncol
  doi: 10.2217/fon.14.238
– volume: 5
  year: 2005
  ident: B18
  article-title: Monocyte and macrophage heterogeneity
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri1733
– volume: 2
  year: 2021
  ident: B83
  article-title: Vaccine for glioma
  publication-title: Nat Cancer
  doi: 10.1038/s43018-021-00228-2
– volume: 3
  year: 2016
  ident: B63
  article-title: Immune evasion strategies of glioblastoma
  publication-title: Front Surg
  doi: 10.3389/fsurg.2016.00011
– volume: 517
  start-page: 293
  year: 2015
  ident: B13
  article-title: The biology of innate lymphoid cells
  publication-title: Nature
  doi: 10.1038/nature14189
– volume: 3
  year: 2018
  ident: B48
  article-title: Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.99048
– volume: 18
  year: 2016
  ident: B25
  article-title: IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/now061
– volume: 20
  year: 2019
  ident: B5
  article-title: Mechanisms of immunotherapy resistance: lessons from glioblastoma
  publication-title: Nat Immunol
  doi: 10.1038/s41590-019-0433-y
– volume: 10
  year: 2009
  ident: B49
  article-title: Dynamics of central and peripheral immunomodulation in a murine glioma model
  publication-title: BMC Immunol
  doi: 10.1186/1471-2172-10-11
– volume: 561
  year: 2018
  ident: B110
  article-title: T Cells engineered to home in on brain cancer
  publication-title: Nature
  doi: 10.1038/d41586-018-05883-7
– volume: 74
  start-page: 390
  year: 2015
  ident: B15
  article-title: Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue
  publication-title: J Neuropathol Exp Neurol
  doi: 10.1097/NEN.0000000000000183
– volume-title: National institute for health and care excellence: clinical guidelines
  year: 2018
  ident: B6
  article-title: Brain tumours (Primary) and brain metastases in adults
– volume: 8
  start-page: 328ra27
  year: 2016
  ident: B79
  article-title: Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aae0105
– volume: 517
  start-page: 35
  year: 2021
  ident: B21
  article-title: Mutant IDH1 promotes phagocytic function of Microglia/Macrophages in gliomas by downregulating ICAM1
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2021.05.038
– volume: 11
  year: 2016
  ident: B74
  article-title: Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma
  publication-title: Oncol Lett
  doi: 10.3892/ol.2016.4142
– volume: 355
  year: 2017
  ident: B66
  article-title: Rescue of exhausted CD8 T cells by PD-1-Targeted therapies is CD28-dependent
  publication-title: Science
  doi: 10.1126/science.aaf0683
– volume: 1617
  start-page: 18
  year: 2015
  ident: B11
  article-title: Interactions of innate and adaptive immunity in brain development and function
  publication-title: Brain Res
  doi: 10.1016/j.brainres.2014.07.050
– volume: 37
  year: 2018
  ident: B32
  article-title: Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the MiR-10a/Rora and MiR-21/Pten pathways
  publication-title: Oncogene
  doi: 10.1038/s41388-018-0261-9
– volume: 8
  year: 2018
  ident: B73
  article-title: Immune checkpoints and innovative therapies in glioblastoma
  publication-title: Front Oncol
  doi: 10.3389/fonc.2018.00464
– volume: 16
  start-page: 81
  year: 2014
  ident: B77
  article-title: IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection
  publication-title: Neuro-oncology
  doi: 10.1093/neuonc/not159
– volume: 5
  year: 2014
  ident: B47
  article-title: How do CD4+ T cells detect and eliminate tumor cells that either lack or express MHC class II molecules
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2014.00174
– volume: 11
  year: 2020
  ident: B34
  article-title: Glioblastoma myeloid-derived suppressor cell subsets express differential macrophage migration inhibitory factor receptor profiles that can be targeted to reduce immune suppression
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.01191
– volume: 7
  year: 2019
  ident: B39
  article-title: Myeloid-derived suppressive cells promote b cell–mediated immunosuppression via transfer of PD-L1 in glioblastoma
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-19-0240
– volume: 10
  year: 2014
  ident: B117
  article-title: Temozolomide induces autophagy via ATM-AMPK-ULK1 pathways in glioma
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2014.2151
– volume: 25
  year: 2019
  ident: B68
  article-title: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
  publication-title: Nat Med
  doi: 10.1038/s41591-019-0349-y
– volume: 1
  start-page: 32
  year: 2013
  ident: B72
  article-title: Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-13-0013
– volume: 27
  year: 2015
  ident: B60
  article-title: Immune checkpoint blockade: a common denominator approach to cancer therapy
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2015.03.001
– volume: 9
  start-page: 14643
  year: 2019
  ident: B50
  article-title: Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-51063-6
– volume: 12
  year: 2021
  ident: B67
  article-title: TIGIT and PD-1 immune checkpoint pathways are associated with patient outcome and anti-tumor immunity in glioblastoma
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.637146
– volume: 8
  year: 2017
  ident: B71
  article-title: Targeting immune checkpoints in malignant glioma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.12702
– volume: 14
  year: 2018
  ident: B81
  article-title: Vaccination in the immunotherapy of glioblastoma
  publication-title: Hum Vaccin Immunother
  doi: 10.1080/21645515.2017.1388481
– volume: 22
  year: 2022
  ident: B36
  article-title: Cells in central nervous system disease: diversity, locations and pathophysiology
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-021-00652-6
– volume: 11
  year: 2019
  ident: B27
  article-title: Characterization of dendritic cells and their role in immunotherapy in glioblastoma: from preclinical studies to clinical trials
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers11040537
– volume: 6
  year: 2011
  ident: B92
  article-title: Hypoxia potentiates glioma-mediated immunosuppression
  publication-title: PloS One
  doi: 10.1371/journal.pone.0016195
– volume: 11
  year: 2019
  ident: B116
  article-title: EMT regulation by autophagy: a new perspective in glioblastoma biology
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers11030312
– volume: 9
  year: 2018
  ident: B82
  article-title: Pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with Recurrent/Progressive high grade glioma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.25131
– volume: 14
  year: 2013
  ident: B114
  article-title: Exosomes from murine-derived GL26 cells promote glioblastoma tumor growth by reducing number and function of CD8+T cells
  publication-title: Asian Pac J Cancer Prev
  doi: 10.7314/apjcp.2013.14.1.309
– volume: 12
  year: 2021
  ident: B2
  article-title: Immune checkpoint inhibitors in human glioma microenvironment
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.679425
– volume: 24
  year: 2023
  ident: B61
  article-title: A2AR as a prognostic marker and a potential immunotherapy target in human glioma
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms24076688
– volume: 19
  year: 2019
  ident: B59
  article-title: Identification of 3 subpopulations of tumor-infiltrating immune cells for malignant transformation of low-grade glioma
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-019-0972-1
– volume: 10
  year: 2021
  ident: B65
  article-title: The promising IgSF11 immune checkpoint is highly expressed in advanced human gliomas and associates to poor prognosis
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.608609
– volume: 124
  year: 2014
  ident: B40
  article-title: Accumulation of 4-1BBL+ b cells in the elderly induces the generation of granzyme-b+ CD8+ T cells with potential antitumor activity
  publication-title: Blood
  doi: 10.1182/blood-2014-03-563940
– start-page: 15
  volume-title: Principles of neuro-oncology: brain & skull base
  year: 2021
  ident: B1
  article-title: Epidemiology of brain tumor
  doi: 10.1007/978-3-030-54879-7_2
– volume: 10
  start-page: 3850
  year: 2019
  ident: B108
  article-title: Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-11719-3
– volume: 132
  year: 2013
  ident: B107
  article-title: Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model
  publication-title: Int J Cancer
  doi: 10.1002/ijc.27712
– volume: 13
  year: 2011
  ident: B29
  article-title: Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/nor042
– year: 2018
  ident: B70
  article-title: Overview of basic immunology and translational relevance for clinical investigators
  publication-title: Immunotherapy
  doi: 10.1007/978-3-030-02505-2_1
– volume: 89
  year: 2003
  ident: B80
  article-title: Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6601268
– volume: 143
  year: 2019
  ident: B69
  article-title: Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment
  publication-title: J Neurooncol
  doi: 10.1007/s11060-019-03172-5
– volume: 16
  start-page: 146
  year: 2019
  ident: B101
  article-title: CCAAT/Enhancer-binding protein delta regulates the stemness of glioma stem-like cells through activating PDGFA expression upon inflammatory stimulation
  publication-title: J Neuroinflamm
  doi: 10.1186/s12974-019-1535-z
– volume: 103
  year: 2017
  ident: B4
  article-title: Extent of resection in glioma-a review of the cutting edge
  publication-title: World Neurosurg
  doi: 10.1016/j.wneu.2017.04.041
– volume: 121
  year: 2020
  ident: B100
  article-title: 3-bromopyruvate inhibits the malignant phenotype of malignantly transformed macrophages and dendritic cells induced by glioma stem cells in the glioma microenvironment via MiR-449a/MCT1
  publication-title: Biomedicine Pharmacothe
  doi: 10.1016/j.biopha.2019.109610
– volume: 218
  year: 2020
  ident: B41
  article-title: Activation of 4-1BBL+ b cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma
  publication-title: J Exp Med
  doi: 10.1084/jem.20200913
– volume: 25
  year: 2019
  ident: B85
  article-title: Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0337-7
– ident: B14
– volume: 15
  year: 2012
  ident: B42
  article-title: Immune surveillance in the central nervous system
  publication-title: Nat Neurosci
  doi: 10.1038/nn.3161
– volume: 8
  year: 2015
  ident: B55
  article-title: Endogenous FOXP3 inhibits cell proliferation, migration and invasion in glioma cells
  publication-title: Int J Clin Exp Med
– volume: 9
  year: 2019
  ident: B112
  article-title: Evaluation of serum extracellular vesicles as noninvasive diagnostic markers of glioma
  publication-title: Theranostics
  doi: 10.7150/thno.33114
– volume: 131
  year: 2016
  ident: B7
  article-title: The 2016 world health organization classification of tumors of the central nervous system: a summary
  publication-title: Acta Neuropathol
  doi: 10.1007/s00401-016-1545-1
– volume: 38
  year: 2017
  ident: B9
  article-title: The neuropathological basis to the functional role of Microglia/Macrophages in gliomas
  publication-title: Neurol Sci
  doi: 10.1007/s10072-017-3002-x
– volume: 26
  year: 2018
  ident: B87
  article-title: Adoptive transfer of IL13Rα2-specific chimeric antigen receptor T cells creates a pro-inflammatory environment in glioblastoma
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2018.02.001
– volume: 165
  year: 2016
  ident: B45
  article-title: Microbiome and anticancer immunosurveillance
  publication-title: Cell
  doi: 10.1016/j.cell.2016.03.001
– volume: 145
  year: 2019
  ident: B109
  article-title: Tumor-targeting nanomedicine carrying the P53 gene crosses the blood–brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma
  publication-title: Int J Cancer
  doi: 10.1002/ijc.32531
– volume: 17
  year: 2015
  ident: B20
  article-title: Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb3090
– volume: 523
  year: 2015
  ident: B10
  article-title: Structural and functional features of central nervous system lymphatic vessels
  publication-title: Nature
  doi: 10.1038/nature14432
– volume: 12
  start-page: 997
  year: 2011
  ident: B76
  article-title: Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(11)70196-6
– volume: 38
  year: 2019
  ident: B90
  article-title: Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model
  publication-title: Oncogene
  doi: 10.1038/s41388-019-0737-2
– volume: 7
  year: 2007
  ident: B22
  article-title: Promiscuity and the single receptor: NKG2D
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri2144
– volume: 17
  year: 2015
  ident: B52
  article-title: Tregs in gliomas – the jury is still out
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/nov034
– volume: 29
  year: 2016
  ident: B106
  article-title: Lactate levels with glioblastoma multiforme
  publication-title: Proc (Bayl Univ Med Cent)
  doi: 10.1080/08998280.2016.11929449
– volume: 14
  year: 2014
  ident: B54
  article-title: Induced regulatory T cells in inhibitory microenvironments created by cancer
  publication-title: Expert Opin Biol Ther
  doi: 10.1517/14712598.2014.927432
– volume: 12
  year: 2017
  ident: B113
  article-title: Systemic T cells immunosuppression of glioma stem cell-derived exosomes is mediated by monocytic myeloid-derived suppressor cells
  publication-title: PloS One
  doi: 10.1371/journal.pone.0169932
– volume: 62
  year: 2013
  ident: B78
  article-title: Phase I trial of a multi-Epitope-Pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-012-1319-0
– volume: 3
  start-page: 309807
  year: 2018
  ident: B58
  article-title: Global immune fingerprinting in glioblastoma reveals immune-suppression signatures associated with prognosis
  publication-title: bioRxiv
  doi: 10.1101/309807
– volume: 4
  year: 2019
  ident: B104
  article-title: Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.123837
– volume: 19
  year: 2018
  ident: B105
  article-title: Glioblastoma chemoresistance: the double play by microenvironment and blood-brain barrier
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms19102879
– volume: 569
  start-page: 87
  year: 2005
  ident: B103
  article-title: Cellular reaction to hypoxia: sensing and responding to an adverse environment
  publication-title: Mutat Research/Fundamental Mol Mech Mutagenesis
  doi: 10.1016/j.mrfmmm.2004.06.054
– volume: 214
  year: 2006
  ident: B23
  article-title: The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression
  publication-title: Immunol Rev
  doi: 10.1111/j.1600-065X.2006.00445.x
– volume: 11
  year: 2019
  ident: B31
  article-title: LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression
  publication-title: Cancer Manag Res
  doi: 10.2147/CMAR.S210545
– volume: 319
  year: 2013
  ident: B56
  article-title: The transcription factor forkhead box P3 (FoxP3) is expressed in glioma cells and associated with increased apoptosis
  publication-title: Exp Cell Res
  doi: 10.1016/j.yexcr.2012.11.018
– volume: 7
  year: 2016
  ident: B115
  article-title: Glioblastoma, hypoxia and autophagy: a survival-prone Ménage-à-Trois
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2016.318
– volume: 14
  year: 2021
  ident: B17
  article-title: P4HA1 down-regulation inhibits glioma invasiveness by promoting M1 microglia polarization
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S299977
SSID ssj0000650103
Score 2.3703606
SecondaryResourceType review_article
Snippet Gliomas are considered one of the most malignant cancers in the body. Despite current therapies, including surgery, chemotherapy, and radiotherapy, these...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1135430
SubjectTerms glioma
glioma cell evasion
immune checkpoints
immune microenvironment
immunotherapy
Oncology
therapy resistance
SummonAdditionalLinks – databaseName: DOAJ Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYqDqgXVGhLFwpypZ6QIpz4sfaxvIQqUfVQJG6WHxOIxGYRu_T3dyYJqyyq6KXX2FGcmUnmG3vmG8a-VgIqa3MsYjYYoCQpClfpVOQYTU3kMFJTvfPVD3N5rb7f6JtRqy_KCevpgXvBHSuTRUpCxYzYOQmJBpOmDt9fBlPG1EEj9HmjYKr_B2tqYNAfY2IU5o7reUuMhZWkLiZaUdbzyBF1fP1_A5kvcyVHzufiHdsaUCP_1q92m72BdodtXg3n4u_ZzzNIzUNXynfLGyr5AD6jVLtRHRsPbea0T8_hd6A9Mj4DKvttFrMFb1redevjt_cNZQx9YNcX579OL4uhV0KRlDHLIiKwkcLmJHWNIMIZqG0FQSpnw1QbCcZMXbYplsKq0kIJVQhWlqHOuYYU5Ue20c5b-MS4VrUKFcYZtXVKgA1aokdTCec7QIQ0YeJZcD4NROLUz-LeY0BBsvYka0-y9oOsJ-xodctDz6Lx2uQT0sZqIhFgdxfQLPxgFv5fZjFhX5516fGDIemGFuZPC095sx2FUDVhu71uV4-SUzq51jhi17S-tpb1kba560i5iQKDyO73_sfq99lbkghlKZTuM9tYPj7BAYKfZTzs7PwPldQDjA
  priority: 102
  providerName: Directory of Open Access Journals
Title Deciphering immune microenvironment and cell evasion mechanisms in human gliomas
URI https://www.ncbi.nlm.nih.gov/pubmed/37274252
https://www.proquest.com/docview/2822705562
https://pubmed.ncbi.nlm.nih.gov/PMC10235598
https://doaj.org/article/46d0cc04bd174c03963c79ead3a61bca
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA_HCeKL-O16ekTwSaim-Wr6IOLXeQgrPriwbyFfXQu73XN379D_3pm0u9zKIkLpQ5M27STTmUkyvx8hLzhL3JjoCx81BChBsKLmKhTRe90gOIxQmO88_qrPJ_LLVE2PyJbeahDg-mBoh3xSk9X81a-fv9-Cwr_BiBPs7etm2SEYIRdIUKKkgAj-BhimCvV0PHj7_Y9ZIasB0s1xIYtaimm_znn4KXuWKgP6H_JC_95Mec06nd0htwe3kr7rx8FdcpS6e-TmeFg4v0--fUyhvci5fjPaYk5Iogvci3ct0Y26LlKcyKfpyuEkGl0kzAtu14s1bTua6fzobN7ilqIHZHL26fuH82IgUyiC1HpTePB8BDMxCNWAl1Hr1BienJC1cZXSImld1dEEXzIjS5PKxJ0zonRNjE0KXjwkx92yS48JVbKRjkMg0phasmScEmDyZID6dQIXakTYVnA2DEjjSHgxtxBxoKwtytqirO0g6xF5ubvloofZ-Ffl99gbu4qIkJ0vLFczOyiclTqyEJj0EWKuwOCDRahq0BvhdOmDG5Hn2760oFEoXdel5eXa4sbajDHER-RR37e7pkSFS9sKSsxer--9y35J1_7IqN2IkYFo-E_-o-ETcotn2g04qqfkeLO6TM_A-dn40zxpAOfP0_I0D-8_QScD0g
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Deciphering+immune+microenvironment+and+cell+evasion+mechanisms+in+human+gliomas&rft.jtitle=Frontiers+in+oncology&rft.au=Rafii%2C+Soumaya&rft.au=Kandoussi%2C+Sarah&rft.au=Ghouzlani%2C+Amina&rft.au=Naji%2C+Oumayma&rft.date=2023-05-19&rft.issn=2234-943X&rft.eissn=2234-943X&rft.volume=13&rft.spage=1135430&rft_id=info:doi/10.3389%2Ffonc.2023.1135430&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon